Truist raised the firm’s price target on Quest Diagnostics (DGX) to $220 from $205 and keeps a Hold rating on the shares. Core trends remain attractive, Q4 volumes were ahead of estimates, and FY26 guidance calls for continued strong organic growth with y/y margin expansion, the analyst tells investors in a research note.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DGX:
- Buy Rating on Quest Diagnostics Driven by Strong 2026 Outlook, Margin Expansion, and Growing High-Margin Segments
- Quest Diagnostics price target raised to $219 from $203 at Baird
- Quest Diagnostics price target raised to $215 from $190 at Citi
- Quest Diagnostics Signals Growth Amid Margin Pressures
- Quest Diagnostics price target raised to $220 from $215 at Jefferies